Welcome to our dedicated page for Zevra Therapeutics news (Ticker: ZVRA), a resource for investors and traders seeking the latest updates and insights on Zevra Therapeutics stock.
Zevra Therapeutics, Inc. (symbol: ZVRA) is a pioneering rare disease company dedicated to developing transformational therapies for conditions with limited or no treatment options. By combining science, data, and patient needs, Zevra aims to deliver life-changing solutions to individuals living with rare diseases. Their mission is to address these unmet medical needs through unique, data-driven development and commercialization strategies.
Zevra Therapeutics utilizes its proprietary Ligand Activated Therapy (LAT) approach to create improved prodrug versions of FDA-approved medications. These prodrugs target high-need areas such as pain management, ADHD, and other central nervous system diseases. Through this innovative technology, Zevra is overcoming complex drug development challenges and making new therapies accessible to the rare disease community.
Recent achievements include significant advancements in their pipeline projects, particularly in pain and ADHD treatment. The company is also known for its strategic partnerships, which enhance its research and development capabilities and accelerate the commercialization of its therapies. Financially, Zevra has a solid foundation, allowing it to focus on its core mission of addressing rare diseases and improving patients' lives.
For up-to-date information, news, and latest developments, Zevra encourages stakeholders to stay connected through their official contact points:
- Nichol Ochsner: +1 (732) 754-2545, nochsner@zevra.com
- Russo Partners: David Schull: +1 (858) 717-2310, david.schull@russopartnersllc.com
- Russo Partners: Ignacio Guerrero-Ros, Ph.D.: +1 (646) 942-5604, ignacio.guerrero-ros@russopartnersllc.com
Zevra Therapeutics (ZVRA) has launched a new disease state awareness campaign called 'Learn NPC, Read Between the Signs' on Rare Disease Day, February 28, 2025. The initiative aims to improve early recognition and diagnosis of Niemann-Pick disease type C (NPC), an ultra-rare, progressive, and neurodegenerative lysosomal storage disorder.
The campaign, launched through www.LearnNPC.com, provides educational resources and testing information for healthcare professionals to better identify NPC, which is often challenging to diagnose due to its varying age of onset and diverse symptom presentation.
The National Niemann-Pick Disease Foundation (NNPDF) has expressed support for the campaign, highlighting its importance in increasing disease awareness among healthcare professionals. The initiative includes resources such as disease summaries, diagnostic challenges, symptom overviews, and testing options for suspected NPC cases.
Zevra Therapeutics (ZVRA) has entered into an agreement to sell its Rare Pediatric Disease Priority Review Voucher (PRV) for $150 million in gross proceeds. The transaction is expected to close within 30-45 days, subject to customary conditions.
The PRV was awarded to Zevra in September 2024 following FDA approval of MIPLYFFA™ (arimoclomol), a treatment for neurological manifestations of Niemann-Pick disease type C in patients 2 years and older. The non-dilutive capital will support the commercial launches of MIPLYFFA™ and OLPRUVA®, along with advancing the company's rare disease pipeline.
Zevra Therapeutics (ZVRA), a commercial-stage company specializing in rare disease therapies, has scheduled its fourth quarter and full year 2024 financial results announcement for Tuesday, March 11, 2025. The company will release its financial results after market close, followed by a conference call and audio webcast at 4:30 p.m. ET.
Investors can access the webcast through Zevra's investor relations website, with dial-in options available for both U.S. (800-245-3047) and international (+1-203-518-9765) participants using Conference ID: ZVRAQ424. A replay of the webcast will be available for 90 days following the presentation.
Zevra Therapeutics (NASDAQ: ZVRA), a commercial-stage rare disease therapy company, has announced its participation in two major investor conferences in March 2025. The company's executive leadership team will present at the TD Cowen 45th Annual Health Care Conference on March 5, 2025, at 10:30 a.m. ET, and the 37th Annual ROTH Conference on March 17, 2025, at 1:00 p.m. PT.
Management will be available for one-on-one meetings with registered attendees at both conferences. Interested parties can access live webcasts of the presentations through the 'Events & Presentations' section on Zevra's Investor Relations website at investors.zevra.com.
Zevra Therapeutics (ZVRA) announced its participation in the 21st Annual WORLDSymposium™, where it will receive a 2025 New Treatment Award for MIPLYFFA™. Eight abstracts related to MIPLYFFA (arimoclomol) have been accepted for poster presentation, with one selected for oral presentation by Dr. Eugen Mengel.
MIPLYFFA is approved for treating neurological manifestations of Niemann-Pick disease type C (NPC) in patients 2 years and older, used in combination with miglustat. The featured presentation will discuss efficacy results from a 12-month double-blind randomized trial using the re-scored 4-domain NPC Clinical Severity Score.
The poster presentations will cover various aspects including gene expression, real-world treatment data, regulatory journey, safety profiles, and long-term efficacy. E-posters will be available to registered attendees from February 4, 2025, through the WORLDSymposium mobile app, with on-demand access extending to March 14, 2025. The symposium takes place February 3-7, 2025, in San Diego, CA.
Zevra Therapeutics (ZVRA), a commercial-stage rare disease therapeutics company, has announced its participation in two major investor conferences in February 2025. The company's executive leadership team will present at the Guggenheim Securities SMID Cap Biotechnology Conference on February 5 at 2:30 p.m. ET, and the Oppenheimer & Co. 35th Annual Healthcare Life Sciences Conference on February 12 at 3:20 p.m. ET.
Management will be available for one-on-one meetings with registered attendees at both conferences. Interested parties can access live webcasts of the presentations through the 'Events & Presentations' section on Zevra's Investor Relations website at investors.zevra.com.
Zevra Therapeutics (ZVRA) announced its upcoming addition to the Nasdaq Biotechnology Index (NBI) effective December 23, 2024, as part of the annual index reconstitution. The inclusion reflects the company's meeting of eligibility requirements, including minimum market capitalization, average daily trading volume, and biotechnology industry classification.
The NBI tracks the performance of biotechnology and pharmaceutical securities listed on Nasdaq under a modified capitalization-weighted methodology. CEO Neil F. McFarlane highlighted this as a transformational year for Zevra, noting that the index inclusion will raise the company's profile among biotech funds and portfolio managers.
Zevra Therapeutics (ZVRA) announced organizational changes as part of its transformation into a rare disease therapeutics company. The company is consolidating its development and scientific functions under CMO Adrian Quartel, who will oversee clinical development, quality assurance, and regulatory affairs.
Key changes include the departure of Chief Development Officer Christal Mickle and Chief Scientific Officer Sven Guenther in December 2024. The company is eliminating positions in CMC and Clinical Development, discontinuing in-house drug discovery activities, and closing laboratories in Iowa and Virginia. Future early R&D will be outsourced.
These changes align with Zevra's 2025 Strategic Plan focusing on late-stage clinical and commercial opportunities, built on four pillars: Commercial Excellence, Pipeline and Innovation, Talent and Culture, and Corporate Foundation.
Zevra Therapeutics (NASDAQ: ZVRA) has announced its participation in two major investor conferences in December 2024. President and CEO Neil F. McFarlane will present at the Piper Sandler 36th Annual Healthcare Conference on December 4 at 10:30 a.m. ET, and the Oppenheimer Movers in Rare Disease Summit on December 12 at 2:45 p.m. ET.
Management will be available for one-on-one meetings with registered attendees at both events. The Piper Sandler fireside chat will be available via webcast through the company's investor relations website.
Zevra Therapeutics (ZVRA) announces the commercial availability of MIPLYFFA™ (arimoclomol), the first FDA-approved treatment for Niemann-Pick disease type C (NPC). The medication is indicated for use with miglustat to treat neurological manifestations in patients 2 years and older. The company reports early adoption exceeding expectations, with product now available for shipment within their guided 8-12 week post-approval timeframe. AmplifyAssist™, Zevra's comprehensive patient support program, provides insurance coverage education, copay assistance, and therapy management counseling to facilitate patient access.
FAQ
What is the current stock price of Zevra Therapeutics (ZVRA)?
What is the market cap of Zevra Therapeutics (ZVRA)?
What does Zevra Therapeutics, Inc. specialize in?
What is the company's mission?
What is the Ligand Activated Therapy (LAT) approach?
Which areas of medical needs does Zevra's technology target?
Who are the primary contacts for investor relations?
How does Zevra ensure the financial stability of their projects?
What recent achievements has Zevra made?
What kind of partnerships does Zevra engage in?
How can stakeholders stay updated with Zevra's latest news?
What is the significance of Zevra’s prodrug development?
